BioCryst Pharma (BCRX) Likely to Report Upside to Orladeyo Estimates, Cowen Would Add Here
Tweet Send to a Friend
Cowen analyst Ken Cacciatore reiterated an Outperform rating and $21.00 price target on BioCryst Pharma (NASDAQ: BCRX) expecting to see ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
